newsfilter
← Latest News
Business Wire·

Pulse Biosciences Completes Enrollment in the PRECISE-BTN Clinical Study Evaluating the nPulse™ Vybrance™ Percutaneous Electrode System for Symptomatic Benign Thyroid Nodules

Completed 100 patient enrollment across three U.S. sites; first patient enrolled completed 12-month follow-up Pulse Biosciences, Inc. (NASDAQ:PLSE), developer of the novel nPulse™ technology using proprietary